Sleep Cycle AB (publ) (STO:SLEEP)
Sweden · Delayed Price · Currency is SEK | Market Cap | 491.73M +3.6% |
| Revenue (ttm) | 211.22M -17.7% |
| Net Income | 11.96M -79.9% |
| EPS | 0.59 -79.8% |
| Shares Out | 20.28M |
| PE Ratio | 41.12 |
| Forward PE | 29.11 |
| Dividend | 0.53 (2.19%) |
| Ex-Dividend Date | Apr 14, 2026 |
| Volume | 1,567 |
| Open | 24.20 |
| Previous Close | 24.60 |
| Day's Range | 24.20 - 24.25 |
| 52-Week Range | 14.84 - 27.70 |
| Beta | 0.01 |
| Analysts | n/a |
| Price Target | 29.50 (+21.65%) |
| Earnings Date | Oct 23, 2026 |
About Sleep Cycle AB
Sleep Cycle AB (publ) engages in the development of sleep analysis applications in Sweden and internationally. It offers Sleep Cycle, an application that provides sleep-related solutions, including smart alarm, sleep stages and aid, and sound recordings; and Luma, an AI-driven sleep coach. The company was incorporated in 2001 and is headquartered in Gothenburg, Sweden. [Read more]
Financial Performance
In 2025, Sleep Cycle AB's revenue was 247.88 million, a decrease of -5.22% compared to the previous year's 261.53 million. Earnings were 53.21 million, a decrease of -15.06%.
Financial StatementsAnalyst Summary
The average 12-month stock price target for SLEEP is kr 29.50, which is an increase of 21.65% from the latest price.
News
Sleep Cycle AB Earnings Call Transcript: Q3 2026
Q3 adjusted EBIT margin reached 29.7% as record B2B revenue partly offset weaker consumer sales. A SEK 35 million annual cost reduction is underway, while Apnea Alert and the proposed Audiowell deal shape the next growth phase.
Sleep Cycle AB Quarterly report: Q3 2026
Sleep Cycle AB has published its Q3 2026 quarterly earnings report on October 23, 2026.
Sleep Cycle AB Slides: Q3 2026
Sleep Cycle AB has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 23, 2026.
Sleep Cycle AB Earnings Call Transcript: Q2 2026
Revenue declined 20% year-over-year, but B2B revenue grew nearly 30% and now forms 15% of total revenue. Strategic focus is shifting toward B2B and tech licensing, with sleep apnea regulatory approval targeted for 2027. Adjusted EBIT margin was nearly 7%.
Sleep Cycle AB Quarterly report: Q2 2026
Sleep Cycle AB has published its Q2 2026 quarterly earnings report on August 26, 2026.
Sleep Cycle AB Slides: Q2 2026
Sleep Cycle AB has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 26, 2026.
Sleep Cycle AB Earnings Call Transcript: Q1 2026
Q1 2026 saw a planned revenue dip as investments in new growth pillars and platform expansion accelerated. B2B revenue surged 42% year-over-year, now nearly 15% of total revenue, while the sleep apnea solution advances toward a 2027 launch.
Sleep Cycle AB Quarterly report: Q1 2026
Sleep Cycle AB has published its Q1 2026 quarterly earnings report on April 29, 2026.
Sleep Cycle AB Slides: Q1 2026
Sleep Cycle AB has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 29, 2026.
Sleep Cycle AB Earnings Call Transcript: Q4 2025
Net sales declined amid a soft consumer market, but profitability and cash flow remained strong. Rapid B2B growth and MedTech initiatives are driving a strategic transformation, with 2026 set as an investment year and growth expected to resume in 2027.
Sleep Cycle AB Annual report: Q4 2025
Sleep Cycle AB has published its Q4 2025 annual report on February 4, 2026.
Sleep Cycle AB Quarterly report: Q4 2025
Sleep Cycle AB has published its Q4 2025 quarterly earnings report on February 4, 2026.
Sleep Cycle AB Slides: Q4 2025
Sleep Cycle AB has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 4, 2026.